RxDoctor Payments DataLook up a doctor →

Marcelino Albuerne, MD

Geriatric Medicine · Catonsville, MDNPI 1306817341

Payments from drug & device makers

$13,711in general payments, 2019–2025

Across 711 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Amgen$1K
  • AstraZeneca$1K
  • GSK$921
  • Novo Nordisk$810
  • Amarin Pharma, Inc.$768
  • plus $8K from 44 others

What the payments were for

  • Food & beverage$13,61799%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,711 in reported general payments places this provider in the 90th percentile of 112 geriatric medicine providers in Maryland.

See all geriatric medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$84,695
Medicare patients
223
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$84,628
XareltoRivaroxaban65$36,477
DovatoDolutegravir Sodium/Lamivudine27$35,262
XifaxanRifaximin23$34,678
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$23,559
EntrestoSacubitril/Valsartan40$16,018
OzempicSemaglutide11$13,370
JardianceEmpagliflozin14$13,096
JanuviaSitagliptin Phosphate15$11,749
GemtesaVibegron28$11,521
Atorvastatin Calcium507$10,395
MyrbetriqMirabegron16$9,972
LinzessLinaclotide12$6,916
Losartan Potassium219$4,816
Amlodipine Besylate404$4,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$428$84,628129 claims
Johnson & JohnsonXarelto$1,476$36,47765 claims
Viiv Healthcare CompanyDovato$55$35,26227 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$151$34,67823 claims
GSKTrelegy Ellipta$921$23,55921 claims
Boehringer IngelheimJardiance, Synjardy Xr$336$17,49436 claims
NovartisEntresto$705$16,01840 claims
Novo NordiskOzempic$810$13,37011 claims
MerckJanuvia$455$11,74915 claims
Sumitomo Pharma America, Inc.Gemtesa$336$11,52128 claims
Astellas Pharma US IncMyrbetriq$208$9,97216 claims
AbbVieLinzess$232$6,91612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 geriatric medicine providers in Maryland.

Other geriatric medicine in Catonsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →